NCT05388877View on ClinicalTrials.gov

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

November 19, 2024

Study Completion Date

June 2, 2025

Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Malignant Neoplasm in the Central Nervous SystemMetastatic Melanoma
Interventions
DRUG

Dabrafenib

Given PO

DRUG

MEK-1/MEKK-1 Inhibitor E6201

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05388877 - E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma | Biotech Hunter | Biotech Hunter